The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers.
 
James Melotek
No Relationships to Disclose
 
Tanguy Y. Seiwert
Honoraria - Celgene
 
Elizabeth A. Blair
No Relationships to Disclose
 
Theodore G. Karrison
No Relationships to Disclose
 
Nishant Agrawal
No Relationships to Disclose
 
Louis Portugal
No Relationships to Disclose
 
Zhen Gooi
No Relationships to Disclose
 
Kerstin Stenson
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I); Amgen (I); Biogen (I); Celgene (I); Gilead Sciences (I); Horizon Pharma (I); Intuitive Surgical (I); Isis Pharmaceuticals (I); Merck (I); Oganobo (I); Pfizer (I); Regeneron (I); Seagen (I); Teva (I)
Patents, Royalties, Other Intellectual Property - I recieve royalties for writing several "Up to Date " chapters per year
 
Ryan J. Brisson
No Relationships to Disclose
 
Saba Arshad
No Relationships to Disclose
 
Allison Dekker
No Relationships to Disclose
 
Sara Kochanny
No Relationships to Disclose
 
Vassiliki Saloura
No Relationships to Disclose
 
Michael T. Spiotto
No Relationships to Disclose
 
Victoria Meucci Villaflor
No Relationships to Disclose
 
Daniel J. Haraf
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech; Leidos Biomedical Research; Lilly; Merck; Merck Serono; Regeneron; Takeda; VentiRx